Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis

Supporting evidence

• Review decision

• Review decision – July 2019

• Review decision paper (PDF 245 KB)

  Published:

  31 July 2019

• Matrix of stakeholders (PDF 180 KB)

  Published:

  31 July 2019